Improving Postdischarge Outcomes in Acute Heart Failure

about

Improving Postdischarge Outcomes in Acute Heart Failure

Item

http://www.wikidata.org/entity/Q57628371

description

wetenschappelijk artikel

@nl

wissenschaftlicher Artikel

@de

name

Improving Postdischarge Outcomes in Acute Heart Failure

@en

Improving Postdischarge Outcomes in Acute Heart Failure

@nl

type

Item

label

Improving Postdischarge Outcomes in Acute Heart Failure

@en

Improving Postdischarge Outcomes in Acute Heart Failure

@nl

prefLabel

Improving Postdischarge Outcomes in Acute Heart Failure

@en

Improving Postdischarge Outcomes in Acute Heart Failure

@nl

P1476

Improving Postdischarge Outcomes in Acute Heart Failure

@en

P2093

Andrew P Ambrosy

http://www.w3.org/2001/XMLSchema#string

Elena-Laura Antohi

http://www.w3.org/2001/XMLSchema#string

Ovidiu Chioncel

http://www.w3.org/2001/XMLSchema#string

Peter S Pang

http://www.w3.org/2001/XMLSchema#string

Sean P Collins

http://www.w3.org/2001/XMLSchema#string

Vlad Anton Iliescu

http://www.w3.org/2001/XMLSchema#string

P2860

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

Targeting myocardial substrate metabolism in heart failure: potential for new therapies

The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study

Molecular and cellular basis of viable dysfunctional myocardium.

Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries.

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Spironolactone for heart failure with preserved ejection fraction.

P304

e475-e486

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MJT.0000000000000791

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Aldo P Maggioni

Javed Butler

Alexandre Mebazaa

P698

29985826

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

P932

6114135

http://www.w3.org/2001/XMLSchema#string